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human cytotoxic T lymphocyte clone recognizing a wild-type
p53-derived peptide
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ABSTRACT A cytotoxic T lymphocyte (CTL) clone gen-
erated in vitro from the peripheral blood of a healthy HLA-
A2-positive individual against a synthetic p53 protein-derived
wild-type peptide (L9V) was shown to kill squamous carci-
noma cell lines derived from two head and neck carcinomas,
which expressed mutant p53 genes, in a L9VyHLA-A2 specific
and restricted fashion. Thus, the normal tolerance against
endogenously processed p53 protein-derived self-epitopes can
be broken by peptide-specific in vitro priming. p53 protein-
derived wild-type peptides might thus represent tumor asso-
ciated target molecules for immunotherapeutical approaches.
The molecular and genetic basis for the development of
neoplasia is an abnormal expression of genes and their en-
coded DNA regulatory proteins important for cellular control
of growth, differentiation, and cell death (1–3). Neoplastic
development may result in the presentation of tumor-
associated peptides derived from regulatory intracellular pro-
teins by major histocompatibility complex class I (MHC-I)
molecules on the surface of the malignant cell (4, 5). In healthy
individuals, as well as in cancer patients, such tumor-relevant
peptide–MHC-I complexes may serve as potential targets for
specific HLA-restricted cytotoxic CD81 T cells. Mutations of
the p53 gene are present in more than 50% of all human
malignancies and more than 65% of oral squamous cell
carcinomas (6–8).
MHC-I associated peptides derived from cytosolic proteins
encoded by regulatory genes such as protooncogene and tumor
suppressor genes, might be of particular relevance for the
immunological surveillance and immunotherapy of tumors. If
mutated, these proteins may be overexpressed in a mutant
non-functioning form in the cytosol of the tumor cells. Poten-
tially, this could lead to an increased intracellular proteolysis
and subsequentMHC-I processing of protein derived peptides.
During the last few years, in vitro priming procedures in human
lymphocyte culture systems have led to the generation of
cytotoxic T lymphocytes (CTLs) with specificity for peptides
derived from proteins encoded by various protooncogenes and
tumor suppressor genes such as ras, HER-2yneu, bcryabl, and
p53 (9–11). With a few exceptions (12–14), none of the CTLs
generated were reported to lyse tumor cells endogenously
expressing the particular oncogenic protein. Thus, it is still
uncertain whether CTL recognition of peptides derived from
DNA regulatory proteins play any part in anti-tumor reactivity
in vivo.
In contrast, recent data from studies of human malignant
melanomas have shown that self-peptides derived from intra-
cellular enzymes, structural proteins, and differentiation an-
tigens such as tyrosinase, gp100, BAGE, and the MART-1
differentiation antigens can serve as targets for MHC-I-
restricted CTL reactivity (15–18).
We quantitated the T cells infiltrating squamous cell carci-
nomas of head and neck (SCCHN) cancer patients (19, 20).
T-cell infiltration was found to be strongly correlated with the
capability to propagate tumor infiltrating T lymphocytes in
vitro. Some of these propagated tumor infiltrating T lympho-
cyte cultures displayed a CD31CD81 phenotype and were
capable of killing autologous tumor cells in an MHC-I-
restricted fashion (20). Immunohistological examinations
showed that 23 of 44 SCCHN overexpressed the p53 protein
(19). Thus, we found it of importance to clarify whether
HLA-A21 SCCHN cells, which overexpress p53 protein and
are sensitive to killing by autologous tumor infiltrating T
lymphocytes, are also sensitive to killing by a HLA-A2-
restricted CTL clone, 3C5, generated in vitro (21) against the
p53-derived, HLA-A*0201 binding wild-type peptide, LL-
GRNSFEV (21, 22).
MATERIALS AND METHODS
Cells. The 3C5 CTL clone was generated from a HLA-
A*0201-positive healthy donor by limiting dilution culture of
peripheral blood T cells incubated with transporter associated
with antiqeu processing (TAP)-deficient T2 cells (23) pulsed
with synthetic p53264–272 peptide (21). This peptide displays a
binding motif for HLA-A*0201 (22), the affinity constant (Kd)
being approximately 6 nM (S. Buus, personal communication).
Conditions for removing, phenotyping, and culturing squa-
mous carcinoma cells from head and neck cancer patients have
been described (20). In brief, small pieces of carcinoma tissue
were plated in culture medium. Immediately following plating,
strongly adherent tumor cells grew out. At confluency, the
tumor cells were separated from the plastic by trypsinyEDTA
and passaged. SCC-4 and SCC-9 cells were purchased from
American Type Culture Collection and cultured in ordinary
RPMI 1640 culture medium containing 10% fetal calf serum.
K562 is an erythroleukemia cell line that is sensitive to
natural killer cell cytotoxicity.
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Immunocytochemistry. Immunocytological evaluation was
performed as described (20). In short, SCCHN cells were
grown on chamber slides (Nunc), fixed in 10% formaldehyde
for 2 h, and incubated withmAb against p53 (D0-7; Dako). The
antibody recognizes an epitope in the N terminus between
amino acids 35–45 and reacts with wild-type and most mutant
forms of p53 protein. The avidin–biotin–peroxidase complex
method was used to detect the primary antibody according to
the instructions from the manufacturer (Dako). Reactivity was
obtained after heating the slides for 10 min in a microwave
oven at 600 W. The chromogen used was diaminobenzidine
(Dako). The sections were counterstained with hematoxylin
and mounted for light microscopic examination.
p53 Mutational Analysis. This procedure was carried out on
genomic DNA extracted from SCCHN cells [with the excep-
tion of the SCC-9 line, which already has been analyzed (24)]
by a combination of denaturating gradient gel electrophoresis
and direct sequence analysis as described (25). In brief, 12
genomic DNA fragments covering the entire coding region
and all splice sites of the p53 gene were amplified by PCR and
scanned for mutations by denaturating gradient gel electro-
phoresis. Fragments showing an altered electrophoretic band
pattern were subjected to sequence analysis. The results are
shown in Table 1.
HLA-A Subtyping. SCCHN cells were incubated with an
anti-HLA-A2 mAb (HB82, American Type Culture Collec-
tion) and their HLA-A2 phenotype confirmed by flow cytom-
etry (Becton Dickinson). The verification of the A*0201
subtype was established with a DNA sequencing-based typing
method (26). In brief, tumor cell mRNA was reverse tran-
scribed into cDNA using standard techniques and PCR am-
plified with an HLA-A locus-specific primer pair. The typing
was performed by direct cycle-sequencing of the PCR product
using an automated sequencer (ABI 373; Applied Biosystems).
The actual assignment of the alleles was done by comparing the
sequence obtained with a data base containing all known
alleles within the HLA-A locus.
Peptide Pulsing and Cytotoxicity Assay. For peptide pulsing
of T2 cells, L9V (p53, 264–272) or G11V (p53, 187–197)
synthetic peptides and human b2 microglobulin (b2m) were
added to 51chromium-labeled T2 cells (see below) at 50 mgyml
and 3 mgyml, respectively, for 1 h at 378C. The L9V and the
G11V peptides show comparable efficiency in upregulation of
HLA-A2 expression on T2 cells following peptide pulsing (21).
Target cells were labeled with sodium–51chromate and specific
lysis was measured in replicates of four cytotoxicity assay
cultures at titered effector:target cell ratios after 4 h incubation
(20). Spontaneous release never exceeded 20% of the total
51chromium release. Cold target cell blocking experiments
were performed with titered numbers of ‘‘cold’’ to ‘‘hot’’
targets. Cold T2 target cells were pulsed for 1 h with L9V or
G11V peptides.
An ascites form of the anti-monomorphic MHC-I antibody
w6y32, used at a final concentration of 1:1000, was tested for
inhibition of killing. An ascites preparation containing mAb of
an irrelevant specificity was used for comparison.
TNF Release Assay. Stimulator cells, (3 3 104) were added
to 33 103 CTL in 100 ml of RPMI 1640 containing 10% human
serum supplemented with 10 unitsyml of recombinant (r)
interleukin 2 (Eurocetus, Amsterdam). After 24 h, 50 ml of the
supernatant was harvested and mixed with 3 3 104 tumor
necrosis factor (TNF)-sensitive WEHI-172-2 cells (27) in 50 ml
of medium. The amount of released TNF was estimated by
comparing the effect of known concentrations of rTNF-b
(Pepro Tech, Rocky Hill, NJ) on WEHI-172-2 survival. TNF
release from CTL cultured without tumor cells (20–30 pgyml)
was subtracted from TNF values shown in Table 1.
RESULTS
SCCHN Carcinoma Lines and 3C5 CTL Recognition. The
HLA*0201-restricted p53 L9V peptide-specific CTL clone (21,
28), 3C5, was tested for recognition and cytotoxic activity on
five different SCCHN cell lines depicted in Table 1. Except for
the SC-46 line, all the SCCHN cell lines were HLA-A*0201-
positive as revealed by flow cytometry and HLA-A subtyping.
The carcinoma cell lines established in our own laboratory
(SC-31, SC-46, SC-49) were studied from their second in vitro
passage onwards. Using an immunocytological technique,
more than 50% of the SCC-4 and SC-49 cells stained positive
for the p53 gene product, whereas the remaining three cell
lines were negative. Except for the SCC-9 line, the p53
mutations shown in Table 1 were analyzed by denaturating
gradient gel electrophoresis and direct sequence analysis. As
shown in Table 1, exposure of 3C5 to SCC-9 or SC-49 cells
resulted in high levels of CTL-derived TNF production,
whereas no TNF could be shown by 3C5 CTL cocultured with
the three remaining SCCHN cell lines. In agreement with the
TNF data, Table 1 further demonstrates that the 3C5 clone
killed only the SCC-9 and SC-49 carcinoma cells and that this
killing could be blocked 40–50% in the presence of anti-
MHC-I antibody (w6y32 mAb) in the cytotoxicity culture. It
should be noted that the natural killer cell-sensitive target,
K562, was not killed by 3C5 CTLs.
HLA-A2yp53 L9V Peptide-Specific Killing Is Blocked by
SC-49 and SCC-9 Carcinoma Cells. Data in Fig. 1A show the
HLA-A2 restriction and p53 peptide specificity of the 3C5
CTL clone. As documented previously (22), the 3C5 CTL










a-MHC-IHLA-A2 MHC-I Exp. Mutation
SCC-4 A*0201yND 260 304 57% pmP151 to S ,1 5 6 4
SCC-9 A*0201y*0101 190 160 0% dc274-85 (fs) 125 25 6 5 40
SC-31 A*0201y*3201 290 327 0% dY236 (fs) ,1 1 6 4
SC-46 A*0301y*0301 0 160 0% GyA sm int4 ,1 21 6 2
SC-49 A*0201y*0201 80 315 63% dc250 (if) 325 63 6 15 50
K562 ,1 2 6 2
SCC cell lines were purchased from the American Type Culture Collection, whereas the SC-31, SC-46, and SC-49 lines were established from
SCCHN patients in our laboratory. The HLA-type was verified by a DNA sequencing-based typing method (26) and expression further confirmed
by flow cytometry (mean fluorescence intensity, MFI) (ND, not determined). HLA-A2 and MHC-I expression was analyzed by using saturating
amounts of the mAbs BB7.2 and W6y32, respectively. p53 protein overexpression (Exp.) was estimated by immunocytochemistry and expressed
as the percentage of p53 protein stained cells. p53 mutation was confirmed by a combination of denaturating gradient gel electrophoresis and direct
sequence analysis (25). pm, Point mutation; dc, deletion of codon; d, deletion; fs, frameshift; sm, splicing mutation; int, intron; if, in-frame. TNF
secretion and percent specific 51chromium release mediated by 3C5 CTL cells exposed to each of the five SCCHN cell lines and the natural killer
cell-sensitive K562 cells are shown. Blocking of cytotoxicity was performed by an ascites form of the mAbW6y32 at a final concentration of 1:1000.
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clone specifically kills HLA-A21 peptide transporter-deficient
(26) L9V-pulsed T2 cells, but not T2 cells pulsed with an
irrelevant p53-derived, HLA-A2 binding peptide (G11V). The
cytotoxic activity was blocked more than 85% in the presence
of cold, i.e., 51chromium-unlabeled, T2 target cells pulsed with
the L9V peptide, and more than 95% by cold SC-49 or SCC-9
(data not shown) carcinoma cells. The cytotoxic activity was
not blocked by cold T2 target cells pulsed with G11V peptide
or by K562 cells. Specific cytotoxicity was inhibited more than
95% in the presence of anti-CD8 mAb, suggesting CD8
dependence of killing.
SC-49-Specific Killing Is Blocked by HLA-A2yp53 L9V and
Is CD8 Dependent and MHC-I Restricted. Data in Fig. 1B
show that 3C5 CTL-mediated killing of SC-49 carcinoma cells
was specifically blocked by cold T2 target cells pulsed with the
L9V peptide, whereas cold T2 cells pulsed with the irrelevant
G11V peptide or K562 cells did not block lysis of SC-49.
Similar data were obtained for killing of the SCC-9 carcinoma
cell line (data not shown). As with L9V-pulsed T2 cells, the
presence of anti-CD8 mAb nearly completely blocked killing
of SC-49 carcinoma cells. Fig. 1B also shows that an Epstein–
Barr virus transformed autologous B cell line (p) and an
autologous fibroblast cell line (pp) were not killed by the 3C5
CTL clone.
DISCUSSION
This study demonstrates for the first time, to the best of our
knowledge, the existence of CTL-mediated, HLAyp53-
peptide-specific and MHC-restricted killing of human carci-
noma cells overexpressing the tumor suppressor protein p53.
The HLA-A2 restricted, peptide-specific killing of SC-49 and
SCC-9 carcinoma cells was documented by its sensitivity to
cold target cell inhibition by L9V- (but not G11V) pulsed T2
cells and by the ability of cold SC-49 and SCC-9 cells to block
killing of L9V-pulsed T2 cells. In addition, the killing was
blocked by anti-CD8 and anti-MHC-I mAbs. The absence of
blocking with cold K562 cells and the lack of killing of
autologous normal cells further argue against the possibility
that 3C5 CTL-mediated killing is due to promiscuous natural
killer cell-like activity or alloreactivity, respectively.
CTL clones recognizing target cells exogenously pulsed with
peptide have been generated against a number of wild-type
and mutant p53 peptides (21, 28). However, p53 peptide-
specific killing by human CTL clones of tumor cells expressing
endogenous p53 protein has not been reported previously.
However, a few murine studies have demonstrated MHC-Iy
mutant p53 peptide-restricted, CTL-mediated killing (12, 13).
As suggested from the data in Table 1, overexpression of p53
protein is not an absolute requirement for killing, since SCC-9
carcinoma cells, in which p53 protein was not detectable, could
also induce both TNF secretion and killing by 3C5 CTLs,
although at lower levels than the p53 overexpressing SC-49
carcinoma cells. Also, overexpression of the p53 protein by
SCCHN cells does not necessarily lead to killing of the cells.
Thus, HLA-A2-positive, p53 protein overexpressing SCC-4
cells were not killed by the 3C5 CTL clone. Most probably,
differences exist in the endogenous p53 protein processing
machinery of SCCHN cell lines generated from different
patients.
Do p53-derived wild-type peptides presented by MHC-I
molecules on tumor cells play any role as target molecules for
CD81 T-cell-mediated immune surveillance? The feasibility to
generate anti-p53 peptide-specific CD81 CTL clones (21, 28)
and to measure CTL precursor frequencies (29) from normal
peripheral T cells of healthy individuals may support this idea.
In addition, according to a recent report, CTL lines were
generated in HLA-A2 transgenic mice immunized with p53
wild-type peptides, including the L9V peptide (30). Such
murine CTL lines killed HLA-A2-positive, p53 overexpressing
breast and colon carcinomas in a CD8-independent fashion,
strongly indicating that p53 derived peptides can serve as
high-affinity target molecules for T-cell receptors in the pro-
cess of immune surveillance.
In conclusion, mutations of the p53 gene (6–8) or other
conditions (31) leading to an overexpression of p53 protein,
are present in more than 50% of all human malignancies. This
FIG. 1. HLA-A2 restricted, peptide-specific killing by 3C5 CTLs of
T2 cells pulsed with the L9V peptide (p53264–272) (A) and of SC-49
SCCHN cells (B). Columns represent mean specific lysis in replicates
of four assay cultures at an effector:target ratio of 25:1. Bars represent
one SD. Notice the absence of killing of two autologous cell lines. p,
An Epstein–Barr virus-transformed B-cell line; pp, fibroblasts. Block-
ing data represent a cold:hot ratio of 20:1.
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demonstration of an HLA-A2yp53 wild-type peptide, recog-
nizable in anMHC-I-restricted fashion by an in vitro generated
CTL clone, suggests that natural tolerance against endogenous
processed p53 protein-derived self-epitopes can be broken by
peptide-specific priming in vitro. p53 protein-derived wild-type
peptides might thus represent tumor associated target mole-
cules for the immune surveillance and, in addition, for immu-
notherapeutical approaches.
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